认知行为疗法、莫达非尼及其联合治疗多发性硬化疲劳的比较有效性(COMBO-MS):一项随机、统计师盲法、平行组试验
COMBO-MS试验在美国两所大学纳入336例多发性硬化伴疲劳成人,随机分入认知行为疗法(CBT)、莫达非尼或联合治疗12周。三组MFIS评分均下降,但组间变化无显著差异;联合治疗未优于单药。莫达非尼相关治疗组最常见不良事件为失眠和焦虑,未发生与研究药物相关的严重不良事件。
要点
- CBT、莫达非尼及联合治疗12周均使MFIS评分临床意义下降,组间差异无统计学意义。
- 联合治疗未较单药带来额外改善。
- 含莫达非尼组最常见不良事件为失眠(各7%)和焦虑(3%与8%)。
核心结论
- 莫达非尼、CBT及联合治疗12周对多发性硬化疲劳的改善相似。
- 联合治疗未较单一干预带来额外改善。
- 需进一步研究睡眠卫生和嗜睡是否影响这些干预对多发性硬化相关疲劳的效果。
研究设计与样本
- 随机、分析者盲法、平行组比较有效性试验,在美国两所大学进行。
- 纳入年龄≥18岁、多发性硬化且疲劳问题(FSS评分≥4)的成人。
- 采用基于网络的治疗分配系统按1:1:1随机分配,采用最小化法,接受CBT、莫达非尼或两者联合治疗12周。
- 统计师对分组设盲,但参与者、研究神经科医生、CBT干预者和协调员未设盲。
- 主要结局为从基线至12周改良疲劳影响量表(MFIS)的变化,采用多元线性回归分析,校正年龄、性别、研究中心、焦虑、疼痛、基线MFIS评分和体力活动。
主要发现
- 2018年11月15日至2021年6月2日,共336例参与者被随机分配治疗(CBT组114例、莫达非尼组114例、联合治疗组108例)。
- 12周时,CBT组(n=103)、莫达非尼组(n=107)和联合治疗组(n=102)的MFIS评分组内下降分别为15.20(SD 11.90)、16.90(15.90)和17.30(16.20)分,均具临床意义。
- 从基线至12周MFIS评分变化组间无差异:相对于联合治疗,CBT的校正总平均差值(MFIS变化评分)为1.88(95%CI -2.21至5.96),莫达非尼为1.20(-2.83至5.23)。
- 含莫达非尼治疗组最常见不良事件包括失眠(莫达非尼组8例[7%],联合治疗组8例[7%])和焦虑(莫达非尼组3例[3%],联合治疗组9例[8%])。
- 未发生与研究药物相关的严重不良事件。
关键数值与推荐
- 疲劳问题定义为FSS评分≥4。
- 主要结局为MFIS评分从基线至12周的变化。
- 相对于联合治疗,CBT的校正总平均差值(MFIS变化评分)为1.88(95%CI -2.21至5.96),莫达非尼为1.20(-2.83至5.23)。
- 含莫达非尼治疗组失眠发生率:莫达非尼组8例(7%),联合治疗组8例(7%);焦虑发生率:莫达非尼组3例(3%),联合治疗组9例(8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 参与者、研究神经科医生、CBT干预者和协调员未对治疗分配设盲。
- 需进一步研究以确定睡眠卫生和嗜睡是否影响这些干预对多发性硬化相关疲劳的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fatigue is one of the most disabling symptoms reported by people with multiple sclerosis. Although behavioural and pharmacological interventions might be partly beneficial, their combined effects have not been evaluated for multiple sclerosis fatigue, or examined with sufficient consideration of characteristics that might affect treatment response. In this comparative effectiveness research trial, we compared the effectiveness of cognitive behavioural therapy (CBT), modafinil, and their combination for treating multiple sclerosis fatigue. METHODS: This randomised, analyst-blinded, parallel-arm, comparative effectiveness trial was done at two universities in the USA. Adults (aged ≥18 years) with multiple sclerosis and problematic fatigue (Fatigue Severity Scale [FSS] score ≥4) were randomly assigned (1:1:1), using a web-based treatment assignment system with minimisation, to receive CBT, modafinil, or both for 12 weeks. Statisticians were masked to group assignment, but participants, study neurologists, CBT interventionalists, and coordinators were not masked to treatment assignment. The primary outcome was the change in Modified Fatigue Impact Scale (MFIS) from baseline to 12 weeks, assessed using multiple linear regression, adjusted for age, sex, study site, anxiety, pain, baselines MFIS score, and physical activity. Analyses were done by intent to treat. The trial was registered with clinicaltrials.gov, NCT03621761, and is completed. FINDINGS: Between Nov 15, 2018, and June 2, 2021, 336 participants were randomly assigned treatment (114 assigned to CBT, 114 assigned to modafinil, and 108 assigned to combination therapy). At 12 weeks, CBT (n=103), modafinil (n=107), and combination therapy (n=102) were associated with clinically meaningful within-group MFIS reductions of 15·20 (SD 11·90), 16·90 (15·90), and 17·30 (16·20) points, respectively. Change in MFIS scores from baseline to 12 weeks did not differ between groups: relative to combination therapy, the adjusted total mean difference in MFIS change score was 1·88 (95% CI -2·21 to 5·96) for CBT and 1·20 (-2·83 to 5·23) for modafinil. Most common adverse events for modafinil-containing treatment groups included insomnia (eight [7%] for modafinil and eight [7%] for combination therapy) and anxiety (three [3%] for modafinil and nine [8%] for combination therapy). INTERPRETATION: Modafinil, CBT, and combination therapy were associated with similar reductions in the effects of multiple sclerosis fatigue at 12 weeks. Combination therapy was not associated with augmented improvement compared with the individual interventions. Further research is needed to determine whether effects of these interventions on multiple sclerosis-related fatigue is influenced by sleep hygiene and sleepiness. No serious adverse events related to the study drug were encountered. FUNDING: Patient-Centered Outcomes Research Institute and National Multiple Sclerosis Society.
引用
- Braley TJ, Ehde DM, Alschuler KN, et al. Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial. Lancet Neurol. 2024. PMID: 39424559. doi:10.1016/S1474-4422(24)00354-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。